Abbott i-STAT 1 System Manual - page 532
BNP - 14
Art: 716969-00J
Rev. Date: 23-May-12
References
1.
Maisel A, Mehra MR. Understanding B-Type Natriuretic Peptide and Its Role in Diagnosing and
Monitoring Congestive Heart Failure, Clin Cornerstone 2005, 7 Suppl 1: S7-17.
2.
Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive Heart Failure in the Community. A
Study of All Incident Cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-
2289.
3.
Wu AH. B-Type Natriuretic Peptide and Its Clinical Utility in Patients with Heart Failure, MLO Med
Lab Obs. 2001 Oct; 33(10): 10-4.
4.
Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a Rapid
B-natriuretic Peptide Assay in Differentiating Congestive Heart Failure From Lung Disease in Pa-
tients Presenting With Dyspnea. J Am Coll Cardiol 2002; 39: 202-209.
5.
Cabanes L, Richaaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, et al. Brain Natriuretic
Peptide Blood Levels in the Differential Diagnosis of Dyspnea. Chest 2001; 120: 2047-2050.
6.
Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natri-
uretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recording.
Circulation 2002; 105: 595-601.
7.
Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, et al. Brain Natriuretic
Peptide is Stable in Whole Blood and Can Be Measured Using a Simple Rapid Assay: Implica-
tions for Clinical Practice. Heart 1997; 78: 594-597.
8.
de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The Prognos-
tic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. N Engl J Med.
2001 Oct 4; 345(14): 1014-21.
9.
Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of Brain Natri-
uretic Peptide in Risk Stratification of Patients with Congestive Heart Failure. J Am Coll Cardiol.
2001 Dec; 38(7): 1934-41.
10. Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG. BNP in hormone-guided
treatment of heart failure. Trends Endocrinol Metab. 2002 May-Jun; 13(4):151-5.
11. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of
Heart Failure Guided by Plasma Aminoterminal Brain Natriuretic Peptide (N-BNP) Concentrations.
Lancet. 2000 Apr 1; 355(9210): 1126-30.
12. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, Mehra MR, Peacock
WF 4th, Fonarow G, Gibler WB, Morrow DA, Hollander J; BNP Consensus Panel. BNP Consen-
sus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitor-
ing, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail.
2004 Sep-Oct;10 (5 Suppl 3): 1-30.
13. Davis M, Espiner E, Richards G, Billings J, Town I, Drennan NA, et al. Plasma Brain Natriuretic Peptide
in Assessment of Acute Dyspnea. Lancet 1994; 343: 440-444.
14. Remme WJ, Swedberg K, Task Force Report. Guidelines for the Diagnosis and Treatment of Chronic
Heart Failure. Eur Heart J 2001; 22: 1527-1560.
15. Maisel A, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid Measurement of
B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002 Jul 18;
347(3): 161-7.
16. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-Type Natriuretic Peptide
and Echocardiographic Determination of Ejection Fraction in the Diagnosis of Congestive Heart Failure
in Patients with Acute Dyspnea. Chest. 2005 Jul; 128(1): 21-9.
17. Rodeheffer RJ. Measuring Plasma B-Type Natriuretic Peptide in Heart Failure: Good to Go in 2004? J
Am Coll Cardiol. 2004 Aug 18; 44(4): 740-9.